Drug-drug-interaction Study of Candesartan, Amlodipine and Atorvastatin

NCT ID: NCT04245046

Last Updated: 2020-02-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 18 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-01-18
• Study Completion Date: 2019-02-18

Brief Summary

Study to determine the potential pharmacokinetic interaction of candesartan cilexetil, atorvastatin as atorvastatin calcium trihydrate and amlodipine as amlodipine besilate at steady state after a multiple oral administration and to monitor the safety of the co-administration of these drugs. This study aims to determine if the steady state study pharmacokinetic parameters of any of the given drugs and the tolerability is altered when administered concomitantly.

Detailed Description

This study was an open-label, comparative, multiple-dose, fixed sequence steady state trial to compare the pharmacokinetic of candesartan cilexetil, atorvastatin as atorvastatin calcium trihydrate, amlodipine as amlodipine besilate given as a multiple dose under fasting conditions in the absence and presence of each other.

Bioanalysis of candesartan, atorvastatin and amlodipine is performed by LC/MS/MS method.

Conditions

Healthy Volunteers

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment A-B-C-ABC

The demographic characteristics of the 18 male subjects were as follows:

• Age: 18-49 years
• Weight: 55-105 kg
• Height: 163-188 cm
• BMI 18.5-29.9 kg/m²

Group Type: EXPERIMENTAL

Candesartan, Amlodipine, Atorvastatin

Intervention Type: DRUG

compare the pharmacokinetic of candesartan cilexetil, atorvastatin as atorvastatin calcium trihydrate, amlodipine as amlodipine besilate from reference products given as a multiple dose

Interventions

Candesartan, Amlodipine, Atorvastatin

compare the pharmacokinetic of candesartan cilexetil, atorvastatin as atorvastatin calcium trihydrate, amlodipine as amlodipine besilate from reference products given as a multiple dose

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Male Caucasian, aged 18 to 50 years, inclusive.
• Body Mass Index (BMI) range within 18.5 - 30.0 Kg/m2.
• Physically and mentally healthy as judged by means of medical and standard laboratory examinations. Medical demographics performed not longer than two weeks before the initiation of the clinical study with significant deviations from the normal ranges.
• Standard ECG assessment is normal
• Informed consent given in written form according to chapter 5.3 of the study protocol.

Exclusion Criteria

• Known allergy to the drugs under investigation or any ingredients or any other related drugs.
• Participation in a relative bioavailability study or in a clinical study within the last 80 days before first study drug administration or blood donation
• Presence of any clinically significant results from laboratory tests, vital sign assessment and electrocardiogram as judged by the investigator. Laboratory tests are performed not longer than two weeks before the initiation of the clinical study.
• Results of CPK or liver or kidney function tests which are outside the reference range.
• Hb test lower than 13.3 g/dl.
• Positive serologic findings
• History of drug or alcohol abuse.
• Subject is a heavy smoker.
• Subject has a history of significant asthma, peptic or gastric ulcer, sinusitis, pharyngitis, renal disorder (impaired renal function), hepatic disorder (impaired hepatic function), cardiovascular disorder, neurological disease such as epilepsy, haematological disorders or diabetes, psychiatric, dermatologic or immunological disorders.
• Subject having at screening examination a sitting blood pressure of less than 110/70 mm Hg or more than or equal to 140/90 mm Hg.
• Subjects who are known or suspected: not to comply with the study directives, not to be reliable or trustworthy, not to be capable of understanding and evaluating the information given to them as part of the formal information policy (informed consent), in particular regarding the risks and discomfort to which they would agree to be exposed, to be in such a precarious financial situation that they no longer weigh up the possible risks of their participation and the unpleasantness they may be involved in.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Midas Pharma GmbH

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mohammed Bader

Role: STUDY_DIRECTOR

International Pharmaceutical Research Center, Jordan

Locations

International Pharmaceutical Research Center

Amman, , Jordan

Countries

Jordan

Other Identifiers

CAAMAT-T1018/71

Identifier Type: -

Identifier Source: org_study_id